Amyloid-Binding Peptides for HIV Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV are ineffective in curing the infection, leading to lifelong medication, significant side effects, and high costs, while also failing to prevent the sexual transmission of HIV, which is exacerbated by amyloidogenic proteins in semen that enhance viral infection efficiency.
Innovation Solution
Development of peptides with specific amino acid sequences, such as those found in SEQ ID NO: 1-11, that inhibit or destroy amyloid fibrils like SEVI and Aβ, reducing viral infection efficiency by at least 50% without affecting DNA polymerase or hematopoietic cells, thereby preventing the formation or destruction of infection-increasing amyloid fibrils.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART is used to suppress HIV replication, then the risk of infection with HIV is reduced due to reduced viral titers, but the infection cannot be avoided and therapy is necessary for life
Solution Approach 1:
The patent applies preliminary action by using amyloid-binding substances (such as D-peptides or cinnamon extract) to prevent SEVI-mediated HIV infection before the infection can establish itself. This preventive approach targets the amyloid-fibril enhancement mechanism, blocking viral entry at an early stage rather than requiring lifelong suppression therapy after infection is established.
2Reliability
If HAART is used to suppress HIV replication, then disease progression is reduced, but the physical and psychological strain caused by long-term medication use is high
Solution Approach 1:
The patent uses amyloid-binding substances as intermediaries that specifically target the amyloid-fibril-HIV interaction mechanism. These substances (D-peptides, cinnamon extract) bind to SEVI or amyloid-beta fibrils, preventing them from enhancing viral infection. This intermediary approach selectively interferes with the harmful amyloid-enhanced infection pathway while avoiding the broad-spectrum toxicity and side effects associated with conventional HAART medications.
3Productivity
If amyloidogenic proteins in semen are present, then sexual transmission of HIV is enhanced, but preventing SEVI-HIV cell interaction should prevent sexual transmission
Solution Approach 1:
The patent converts the harmful effect of amyloidogenic proteins (SEVI) that enhance viral transmission into a beneficial target for prevention. By identifying that SEVI and amyloid-beta fibrils enhance HIV infection, the invention develops amyloid-binding substances that specifically neutralize this enhancement mechanism. The same amyloid-binding mechanism that was initially identified as harmful (increasing infectivity) becomes the target for therapeutic intervention, allowing selective blocking of enhanced transmission while preserving normal biological functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides significantly reduce the infectivity of HIV and other viral infections by inhibiting or destroying amyloid fibrils, offering a potential cure or prevention method for HIV-associated neurological damage and other viral diseases, with minimal side effects and improved treatment efficacy.
Implementation Method 1
synthetic amyloid fibrils made of Aβ 1-40 and Aβ 1-42 can increase the infectivity of the HIV-1 virus... The Aβ fibrils cause a 5 to 20-fold increased infection efficiency of reporter cells that express the HIV-1 receptor CD4... peptides that bind with a high binding affinity to the peptide beta-amyloid
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E
AI summary
The invention relates to an agent for the prophylaxis and/or treatment of HIV and other viral infections. The agent contains, in particular, at least one peptide with an amino acid sequence suitable for the prophylaxis of fibrilla associated with Alzheimer's disease, and/or homologues, fragments and parts of said peptide, for the treatment and/or prophylaxis of HIV and/or other viral infections.